secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K/A
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001140361-23-039343
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio files historical financials of Private Elicio post-merger; Q1 net loss $8.0M, going concern flagged
--------------------------------------------------------------------------------

- Private Elicio net loss of $8.0M for Q1 2023; accumulated deficit $115.0M at March 31, 2023.
- Cash and equivalents of $8.6M at March 31, 2023; negative operating cash flow of $8.1M in Q1.
- Auditor's going concern opinion citing losses, negative cash flows, and need for additional financing.
- Merger with Angion closed June 1, 2023; company renamed Elicio Therapeutics, now trading as ELTX.
- Pro forma combined financials filed; no revenue for Private Elicio in the periods presented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000114036123039343/0001140361-23-039343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000114036123039343/brhc20057283_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-039343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer